Gary Lee
Technik-/Wissenschafts-/F&E-Leiter bei LYELL IMMUNOPHARMA, INC.
Vermögen: 35 179 $ am 31.05.2024
Profil
Gary Lee is currently the Chief Scientific Officer at Lyell Immunopharma, Inc. He previously held the position of Vice President-Cell Therapy at Sangamo Therapeutics, Inc. from 2005 to 2018.
From 2018 to 2022, he served as the Chief Scientific Officer at Senti Sub I, Inc. Dr. Lee completed his undergraduate degree at the California Institute of Technology and obtained a doctorate degree from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LYELL IMMUNOPHARMA, INC.
0,00% | 31.03.2024 | 12 700 ( 0,00% ) | 35 179 $ | 31.05.2024 |
Aktive Positionen von Gary Lee
| Unternehmen | Position | Beginn |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.01.2022 |
Ehemalige bekannte Positionen von Gary Lee
| Unternehmen | Position | Ende |
|---|---|---|
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2022 |
| SANGAMO THERAPEUTICS, INC. | Corporate Officer/Principal | 01.10.2018 |
Ausbildung von Gary Lee
| University of California, Berkeley | Doctorate Degree |
| California Institute of Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Health Technology |
